Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)

Business Type Exporter, Manufacturer, Distributor, Supplier, Trading Company Related Products More Products From This Seller Seller Details Trusted Seller RM702, Unit 1, Building 21, Liuhe Road, Ganjingzi Dist, Dalian, Liaoning, 116091, China peptides in Dalian Compare With Similar Products Shelf Life 18 Months 2 years under recommended storage Solubility Soluble in water Soluble in water or buffered solution Properties The key properties of BPC-157 lie primarily in its ability to regulate multiple biological systems:1) Promoting Angiogenesis: It activates the VEGFR2 and Akt-eNOS pathways, promoting angiogenesis, which is crucial for the healing of tissues lacking blood supply (such as tendons and ligaments)
I think they both have their place
Its about safety, oversight, and results